Analysts Set Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Price Target at $4.79

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has received a consensus recommendation of “Hold” from the eleven ratings firms that are covering the firm, Marketbeat.com reports. Eight analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $4.79.

A number of research analysts recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $4.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. TD Cowen restated a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. StockNews.com assumed coverage on shares of Marinus Pharmaceuticals in a report on Sunday, January 5th. They issued a “sell” rating on the stock. Truist Financial downgraded shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC grew its holdings in Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 12,934 shares during the last quarter. Point72 DIFC Ltd purchased a new position in shares of Marinus Pharmaceuticals during the second quarter valued at approximately $28,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Marinus Pharmaceuticals during the second quarter valued at approximately $64,000. World Investment Advisors LLC bought a new position in shares of Marinus Pharmaceuticals during the third quarter valued at approximately $104,000. Finally, Jacobs Levy Equity Management Inc. raised its holdings in shares of Marinus Pharmaceuticals by 39.5% in the third quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock worth $729,000 after buying an additional 117,255 shares during the period. 98.80% of the stock is owned by institutional investors.

Marinus Pharmaceuticals Stock Up 0.9 %

Shares of Marinus Pharmaceuticals stock opened at $0.54 on Wednesday. The company has a market capitalization of $29.63 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. The stock’s 50-day simple moving average is $0.35 and its 200-day simple moving average is $1.02. Marinus Pharmaceuticals has a 52 week low of $0.22 and a 52 week high of $10.50.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.